Navigation Links
Silence Therapeutics Issued New Patents Covering siRNA Sequences for RNA Interference Therapeutics
Date:9/8/2010

LONDON, Sept. 8 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") announces the issuance of two new patents by the United States Patent and Trademark Office (USPTO) which are broadly directed to double-stranded short interfering RNA (siRNA) sequences against the validated cancer targets epidermal growth factor receptor related protein (EGFR-RP) and vascular endothelial growth factor receptor 1 (VEGFR1).  EGFR-RP and VEGFR1 have been demonstrated to play key roles in the underlying causes of various cancers including abnormal angiogenesis and uncontrolled cell division.  Similar to vascular endothelial growth factor receptor 2 (VEGFR2), VEGFR1 also is implicated in the development and progression of age-related macular degeneration (AMD) and other serious ocular diseases.  The EGFR-RP patent is broadly directed to methods of reducing EGFR-RP with a DNA or RNA molecule, including siRNA molecules.  The sequence covered by the VEGFR1 patent is a potent 25mer siRNA, demonstrating Silence's continued ability to secure meaningful intellectual property protection for its portfolio of 25mer sequences.

"The past several months have seen Silence add a number of high-value patents to its broad RNAi intellectual property portfolio.  Whereas many of these recent issuances have focused on the structural modification of RNAi therapeutics to improve efficacy, today's announcement underscores our efforts to concurrently build critical protection in the equally important areas of siRNA sequences and siRNA delivery," said Philip Haworth, Ph.D., chief executive officer of Silence Therapeutics.  "We are particularly pleased that we have been able to secure an additional patent covering 25mer siRNA sequences, validating our belief that we can build a portfolio of proprietary 25mer siRNA sequences that will provide us an added level of protection in the RNAi space.  Furthermore, the breadth of the issued EGFR-RP pa
'/>"/>

SOURCE Silence Therapeutics plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Silence Therapeutics and AstraZeneca Extend siRNA Development Collaboration
2. Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company
3. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
4. Silence Therapeutics Announces Board Changes
5. Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
6. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
7. Actress and New Mom Keri Russell Joins PKIDs to launch Silence the Sounds of Pertussis Campaign
8. Precision Therapeutics, Inc. Named to Pittsburgh Business Times 2010 Top 100
9. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
10. Reportlinker Adds Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets
11. Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... BOTHELL, Wash. , Sept. 23, 2014   ... a leading developer, manufacturer and marketer of proprietary clinical ... media and precision thermal shipping products ... announced two new additions to its Scientific Advisory Board.  ... and Anthony Davies , PhD. Dr. ...
(Date:9/22/2014)... BARCELONA, Spain , September 23, 2014 ... sponsors to meet health authorities, increasing rigor for trial ... The life sciences industry,s largest TMF survey to date ... sponsors that plan to provide auditors with remote access ... 32% of TMF owners surveyed in the ...
(Date:9/22/2014)... NEW YORK , Sept. 22, 2014 /PRNewswire/ ... is in mature stage. It is largely a ... endoscopy suite expansion. The mergers, acquisitions and partnerships ... Europe . This research service provides details ... competitive environment and pricing trends across the country. ...
Breaking Medicine Technology:BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 2BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 3BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 4BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 5BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 6BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 7Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 2Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 3Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 4Automated Endoscope Reprocessor Market Trends in Western Europe 2Automated Endoscope Reprocessor Market Trends in Western Europe 3
... RoundTable Healthcare Partners ("RoundTable"), an operating-oriented private equity ... today that it has entered into a definitive ... Clinical Innovations, LLC ("Clinical"), to The Pritzker Group, ...  Terms of the transaction were not disclosed. ...
... Amira Pharmaceuticals, Inc. announced today that it has ... lysophosphatidic acid (LPA)-related program, autotaxin.  Autotaxin is an enzyme ... a number of diseases including rheumatoid arthritis, glioblastoma, lung, ... pleased to announce that we have identified an orally ...
Cached Medicine Technology:RoundTable Healthcare Partners Announces Sale of Clinical Innovations, LLC to The Pritzker Group 2Amira Pharmaceuticals Announces the Nomination of an Orally Available Pre-Clinical Candidate in a New LPA-Related Program, an Autotaxin Inhibitor 2
(Date:9/23/2014)... Toronto (PRWEB) September 23, 2014 ... the Canadian specialty market, is now providing U.S. ... its new 160,000-square-foot distribution center coupled with its ... Canadian healthcare industry has historically been difficult for ... to government regulation complexities. As a result of ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 The print ... of the Metro, with a circulation of approximately 327,720 ... component is distributed nationally through a vast social media ... and partner outlets. To explore the digital version of ... features an exclusive interview with Michael Landsberg, host of ...
(Date:9/23/2014)... 2014 Antibiotics revolutionized health care in the ... killed thousands of people. But bacteria are also ... bacteria are popping up more frequently. This week,s ... of new antibiotics and discusses the prospects for ... Why should you finish your pills if you ...
(Date:9/23/2014)... to what is often assumed about single parents, particularly ... The Kinsey Institute has found that single parents of ... as often as singles without children -- and more ... study, "Dating and Sexual Behavior Among Single Parents of ... in the Journal of Sex Research prior ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 On September 23, ... Keith Simmons for an episode. Simmons is the founder of ... believed the audience would like to know. At the start ... the idea to start this magazine?” Simmons replied by saying, ... sales person. In 2005, I quit that and decided to ...
Breaking Medicine News(10 mins):Health News:AmerisourceBergen Paves Path to Canadian Markets 2Health News:AmerisourceBergen Paves Path to Canadian Markets 3Health News:‘Sick, not weak’: Mediaplanet’s "Mental Health” Campaign Dispels Stigmas and Bolsters Support for the One in Five Canadians Suffering Mental Illness 2Health News:Kinsey study of single parents' dating, sexual activity contradicts assumptions 2Health News:My Positive Perspective Airs Episode With the Founder of Traveler of Charleston Magazine 2
... Society for Gastrointestinal Endoscopy (ASGE) and the American Society ... new white paper on the potential role of endoscopic ... like Type 2 diabetes. The white paper ... in both GIE: Gastrointestinal Endoscopy, the peer-reviewed ...
... standards for teaching women and clinicians how to perform ... to detect lumps earlier and save lives. Widely-publicized ... of cancer. The Center for Disease Control reports that ... most common cancer among American females. The National ...
... keep blood vessels open to treat heart disease are ... the Journal of Interventional Cardiology . A case ... of the Detroit Medical Center Cardiovascular Institute, and her ... after the recently marketed Ion stent (Boston Scientific, Natick, ...
... of organic horticultural crops frequently fall below those of ... of organic production. Researchers recently studied the growth and ... with vermicompost and compared the results with plants grown ... area is needed to provide a base of information ...
... has found that people are willing to pay up to 29.91 ... Researchers surveyed the public in the two major urban centres ... were willing to pay in council tax or rent/mortgage payments for ... willing to pay more for greener spaces with greater tree coverage. ...
... poisonous snakes, a group of researchers at the University of ... small black, yellow and red serpent called the Texas coral ... insights into chronic and acute pain and provides new ... combat pain. The venom contains a toxic mixture of ...
Cached Medicine News:Health News:ASMBS and ASGE issue white paper on endoscopic bariatric therapies (EBTs) 2Health News:ASMBS and ASGE issue white paper on endoscopic bariatric therapies (EBTs) 3Health News:Public willing to pay more for greener urban spaces 2Health News:Public willing to pay more for greener urban spaces 3Health News:Snake spills venomous secrets 2Health News:Snake spills venomous secrets 3
... is a leading provider of immunofluorescence assays, ... menu that includes kits for autoimmune diseases, ... miscellaneous conjugates and components. Our Impact IFA ... of substrates and kit sizes to choose ...
... a leading provider of immunofluorescence assays, with ... that includes kits for autoimmune diseases, infectious ... conjugates and components. Our Impact IFA Test ... substrates and kit sizes to choose from. ...
... Medical Professional Diagnostics is a leading provider ... and DFA test menu that includes kits ... as well as miscellaneous conjugates and components. ... a wide assortment of substrates and kit ...
... Medical Professional Diagnostics is a leading provider ... and DFA test menu that includes kits ... as well as miscellaneous conjugates and components. ... a wide assortment of substrates and kit ...
Medicine Products: